More than a third of adults inactive in most deprived places
More than a third of adults living in the country's most deprived areas are not getting enough physical activity, according to new research by Sport England.
The public body warned of a 'postcode lottery' as its findings showed 34% of less affluent adults fell within the category, compared with only 20% from the least deprived areas.
It comes as Sport England announced plans to invest in activity levels in more than 50 new places currently struggling to provide it, including major cities such as Liverpool, Nottingham and Southampton.
Women, people from lower socio-economic groups and black and Asian people still remain less likely to be active than other adults, while less than half of children currently meet the Chief Medical Officer's guidelines for daily physical activity.
A Sport England report published last year found healthy, active lifestyles save the health and care system £10.5 billion a year by relieving pressure on the NHS, preventing chronic illnesses and saving money through reduced use of health services such as mental health support.
The body will partner with local organisations and leaders in 53 places who understand what facilities are available to support people to play sport and get active in their respective communities.
It has been testing its 'Place-based approach' since 2018 by taking a bespoke approach to each area, identifying the major barriers to activity that each place faces and working to dismantle them.
Recent examples include using football, gardening and walking to integrate refugees into the communities, influencing housing plans in Exeter and providing gentle dance classes for older people to help them rehabilitate after a fall.
Sport England chief executive Tim Hollingsworth said: 'It is unacceptable that for many children and adults, their postcode, background and income dictate how active and healthy they can be – even affecting how long they might live.
' Inequality in activity levels damage health and undermine growth; we want to end the postcode lottery for physical activity.
'Uniting the Movement's mission is to make sure we all have the opportunity to lead an active life, which is essential for the growth agenda too. Sport and physical activity are not just good for health; they are acts of economic contribution.'
Chair Chris Boardman said health inequalities had 'become embedded in our communities' and that rising levels of inactive children were 'a ticking time bomb for the long-term health and wealth of the country' that must be addressed urgently.
Sport England invests up to £300 million of National Lottery and Government money annually into projects and programmes that help people get active and play sport.
The full list of places securing new investment was:
– Ashfield– Barnsley– Barking and Dagenham– Blackpool– Boston– Brent– Castle Point– Cheshire East– Cheshire West and Chester– Cumberland– Darlington– Derby– Dudley– East Lindsey– Erewash– Fenland– Gateshead– Gravesham– Great Yarmouth– Harlow– Hartlepool– Ipswich– King's Lynn & West Norfolk– Kingston upon Hull– Kirklees– Knowsley– Leicester– Liverpool– Milton Keynes– North East Lincolnshire– North Northamptonshire– Nottingham– Peterborough– Portsmouth– Rotherham– Sandwell– Sefton– Slough– Southampton– South Tyneside– Spelthorne– Stockton-on-Tees– Stoke-on-Trent– Swindon– Thanet– Thurrock– Tower Hamlets– Walsall– Warrington– West Northamptonshire– West Suffolk– Wirral– Wolverhampton
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Leader Live
28 minutes ago
- Leader Live
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
The Herald Scotland
an hour ago
- The Herald Scotland
Weight loss pill shows promise in new trial
And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. GPs in England will be able to prescribe Mounjaro from Monday (Alamy/PA) An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
North Wales Chronicle
an hour ago
- North Wales Chronicle
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
